drugset / Trial / NCT03991442

BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination

NCT03991442

Phase 3 Completed 257 enrolled Boryung Pharmaceutical Co., Ltd
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this clinical study is to evaluate the efficacy and safety by comparing the BR1010 treatment group to the fimasartan/amlodipine treatment group at Week 8 in patients with essential hypertension who do not adequately respond to Fimasartan/Amlodipine combination

Timeline

Start
2019-06-17
Primary completion
2021-03-02
Completion
2021-03-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Amlodipine Other / unclassified
Subject Fimasartan Small molecule